News & Investors


Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC Delivery Platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The Company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a pre-clinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.

News

Read the latest news about Phospholipid Drug Conjugates (PDCs) for targeted delivery of oncologic payloads.

Read more

Investors

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Cellectar Biosciences's financial performance into perspective.

Read more

CONTACT US

Cellectar‘s goal is to improve the lives of cancer patients through innovation, collaboration,
and the manufacturing of our targeted drug delivery technologies.